Hubei Biocause Pharmaceutical Co., Ltd.

Total Valuation

Hubei Biocause Pharmaceutical Co., Ltd. carries a market capitalization of 7.75B, placing it among publicly traded companies globally. Its enterprise value stands at 39.51B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Hubei Biocause Pharmaceutical Co., Ltd. currently has 4.94B shares outstanding.

Valuation Ratios

The price-to-sales ratio is 0.44, and the price-to-book ratio stands at 1.85.

Enterprise Valuation

On an enterprise value basis, Hubei Biocause Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 5.50 and an EV/FCF ratio of 578.95. The EV/Sales ratio of 0.94 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 5.50 provides insight into valuation relative to core operating earnings.

Financial Position

Hubei Biocause Pharmaceutical Co., Ltd. maintains a current ratio of 2.02, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Taxes

Over the trailing twelve months, Hubei Biocause Pharmaceutical Co., Ltd. has paid -196.66M in income taxes, reflecting an effective tax rate of 56.66.

Stock Price Statistics

Hubei Biocause Pharmaceutical Co., Ltd.'s stock has declined approximately -53.66569% over the past 52 weeks. The 50-day moving average sits at 2.23, while the 200-day moving average is 3.43.

Income Statement

Over the trailing twelve months, Hubei Biocause Pharmaceutical Co., Ltd. generated 42.08B in revenue and converted that into -771.87M in net income, yielding earnings per share of -0.31. EBITDA reached 7.18B, while operating income came in at 7.18B.

Balance Sheet

Hubei Biocause Pharmaceutical Co., Ltd. holds 10.57B in cash and equivalents against 17.56B in total debt, resulting in a net debt position of 9.15B. Total book value stands at 9.92B, with working capital of 17.75B providing operational flexibility.

Cash Flow

After subtracting -68.25M in capital expenditures, free cash flow totaled -68.25M - equivalent to -0.01 per share.

Margins

Hubei Biocause Pharmaceutical Co., Ltd. operates with a gross margin of 35.78, reflecting its pricing power and cost economics. The operating margin of 17.06 and net profit margin of -1.83 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of -33.46 indicates the proportion of earnings distributed to shareholders.

Stock Splits

Hubei Biocause Pharmaceutical Co., Ltd.'s most recent stock split took place on April 12, 2010 with a 20:37 split ratio.

Scores

Hubei Biocause Pharmaceutical Co., Ltd. posts an Altman Z-Score of 0.38, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.